159938 医药
已收盘 09-01 15:00:00
资讯
新帖
简况
前海开源中药股票8月份跌超5% 医药行情拖累8年老将
中金财经 · 16:15
前海开源中药股票8月份跌超5% 医药行情拖累8年老将
港股IPO：普莱医药（江苏）股份有限公司- B递表港交所
同花顺 · 15:05
港股IPO：普莱医药（江苏）股份有限公司- B递表港交所
普莱医药递表港交所 拟于港交所主板上市
同花顺 · 14:36
普莱医药递表港交所 拟于港交所主板上市
普莱医药二次递表港交所 核心产品PL-5为全球首款提交NDA的加南类抗菌肽药物
同花顺 · 12:54
普莱医药二次递表港交所 核心产品PL-5为全球首款提交NDA的加南类抗菌肽药物
普莱医药向联交所递交招股书
同花顺 · 10:40
普莱医药向联交所递交招股书
恒瑞医药HER2 ADC三期数据积极，国产ADC一线治疗竞争力提升｜医药早参
每日经济新闻 · 09:23
恒瑞医药HER2 ADC三期数据积极，国产ADC一线治疗竞争力提升｜医药早参
迪哲医药(688192.SH)：与阿斯利康就舒沃哲®授权许可协议生效
智通财经 · 08:44
迪哲医药(688192.SH)：与阿斯利康就舒沃哲®授权许可协议生效
普莱医药二次递表港交所
同花顺 · 06:42
普莱医药二次递表港交所
股市必读：森萱医药新发布《投资者关系活动记录表》
证券之星 · 01:57
股市必读：森萱医药新发布《投资者关系活动记录表》
力生制药：采立惠（www.cailihui.com）是力生制药子公司青春康源立和医药旗下品牌
证券之星 · 08-31 20:51
力生制药：采立惠（www.cailihui.com）是力生制药子公司青春康源立和医药旗下品牌
亚虹医药（688176）披露2026年半年度报告，8月31日股价下跌0.17%
证券之星 · 08-31 18:48
亚虹医药（688176）披露2026年半年度报告，8月31日股价下跌0.17%
迪哲医药（688192）披露舒沃哲新增适应症上市申请获美国FDA受理，8月31日股价下跌0.66%
证券之星 · 08-31 17:44
迪哲医药（688192）披露舒沃哲新增适应症上市申请获美国FDA受理，8月31日股价下跌0.66%
A股午评：创业板指跌1.29%，影视院线板块爆发，黄金、医药板块跌幅居前
格隆汇 · 08-31 11:33
A股午评：创业板指跌1.29%，影视院线板块爆发，黄金、医药板块跌幅居前
迪哲医药、剧星传媒递表港交所；星环科技通过港交所聆讯｜港交所早参
每日经济新闻 · 08-31 10:26
迪哲医药、剧星传媒递表港交所；星环科技通过港交所聆讯｜港交所早参
政策东风与产业升级交汇，双成药业站在医药价值重估的风口
证券之星 · 08-31 10:10
政策东风与产业升级交汇，双成药业站在医药价值重估的风口
股市必读：白云山新发布《北京市中伦（广州）律师事务所关于广州白云山医药集团股份有限公司2026年第一次临时股东会的法律意见书》
证券之星 · 08-31 08:22
股市必读：白云山新发布《北京市中伦（广州）律师事务所关于广州白云山医药集团股份有限公司2026年第一次临时股东会的法律意见书》
股市必读：亚虹医药中报 - 第二季度单季净利润同比下降60.40%
证券之星 · 08-31 07:41
股市必读：亚虹医药中报 - 第二季度单季净利润同比下降60.40%
股市必读：迪哲医药新发布《迪哲医药：关于重新向香港联交所递交H股发行上市申请并刊发申请资料的公告》
证券之星 · 08-31 03:33
股市必读：迪哲医药新发布《迪哲医药：关于重新向香港联交所递交H股发行上市申请并刊发申请资料的公告》
议程一览｜科创出海，药启新程·2026上海国际医药健康创新与资本大会暨第15届医药CEO论坛（更新至0830）
国泰君安证券研究 · 08-30 22:09
议程一览｜科创出海，药启新程·2026上海国际医药健康创新与资本大会暨第15届医药CEO论坛（更新至0830）
亚虹医药（688176）2026年中报简析：增收不增利
证券之星 · 08-30 06:15
亚虹医药（688176）2026年中报简析：增收不增利
加载更多
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159938","market":"SZ","secType":"STK","nameCN":"医药","latestPrice":0.646,"timestamp":1788246195000,"preClose":0.643,"halted":0,"volume":46022500,"delay":0,"changeRate":0.0047,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":0.003,"latestTime":"09-01 15:00:00","open":0.642,"high":0.647,"low":0.64,"amount":29637000,"amplitude":0.0109,"askPrice":0.646,"askSize":80,"bidPrice":0.645,"bidSize":2138,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788312600000},"marketStatusCode":5,"adr":0,"adjPreClose":0.643,"symbolType":"fund","openAndCloseTimeList":[[1788226200000,1788233400000],[1788238800000,1788246000000]],"highLimit":0.707,"lowLimit":0.579,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":0.261783,"marketValue":0,"turnoverRate":0,"status":0,"floatMarketCap":0},"requestUrl":"/m/hq/s/159938","defaultTab":"news","newsList":[{"id":"2664783493","title":"前海开源中药股票8月份跌超5% 医药行情拖累8年老将","url":"https://stock-news.laohu8.com/highlight/detail?id=2664783493","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664783493?lang=zh_cn&edition=full","pubTime":"2026-09-01 16:15","pubTimestamp":1788250503,"startTime":"0","endTime":"0","summary":"中国经济网北京9月1日讯 在刚过去的8月份，受医药行情拖累，前海开源中药股票A/C单月分别下跌5.45%、5.47%。 前海开源中药股票A/C成立于2018年3月21日，截至2026年8月31日，其成立以来收益率为84.24%、80.90%，累计净值为1.8424元、1.8090元。2018年2月起任前海开源医疗健康灵活配置混合型证券投资基金基金经理。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/01/20260901310528.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/01/20260901310528.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260901/32356438.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","09939","BK1574","BK1515","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664360758","title":"港股IPO：普莱医药（江苏）股份有限公司- B递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2664360758","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664360758?lang=zh_cn&edition=full","pubTime":"2026-09-01 15:05","pubTimestamp":1788246300,"startTime":"0","endTime":"0","summary":"每经AI快讯，8月31日，港交所文件显示，普莱医药（江苏）股份有限公司- B向港交所提交上市申请书，独家保荐人为中信证券。 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260901/c679484908.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260901/c679484908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664836317","title":"普莱医药递表港交所 拟于港交所主板上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2664836317","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664836317?lang=zh_cn&edition=full","pubTime":"2026-09-01 14:36","pubTimestamp":1788244560,"startTime":"0","endTime":"0","summary":"中国上市公司网讯8月31日，普莱医药(江苏)股份有限公司(以下简称“普莱医药”)在港交所提交的上市申请，公司上市材料被正式受理，独家保荐人为中信证券。公开数据显示，普莱医药是一家抗菌 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260901/c679484214.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260901/c679484214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664838491","title":"普莱医药二次递表港交所 核心产品PL-5为全球首款提交NDA的加南类抗菌肽药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2664838491","media":"同花顺","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664838491?lang=zh_cn&edition=full","pubTime":"2026-09-01 12:54","pubTimestamp":1788238440,"startTime":"0","endTime":"0","summary":"8月31日，据港交所披露，普莱医药(江苏)股份有限公司(简称：普莱医药)向港交所主板递交上市申请，中信证券为其独家保荐人。该公司曾于2月13日向港交所提交上市申请。招股书显示，普莱医药是 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260901/c679482393.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260901/c679482393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664876978","title":"普莱医药向联交所递交招股书","url":"https://stock-news.laohu8.com/highlight/detail?id=2664876978","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664876978?lang=zh_cn&edition=full","pubTime":"2026-09-01 10:40","pubTimestamp":1788230400,"startTime":"0","endTime":"0","summary":"据联交所8月31日披露，普莱医药(江苏)股份有限公司向联交所提交上市申请，拟香港主板上市，中信证券香港为保荐人。公司是一家抗菌肽（“AMP”）生物医药公司，专注于抗感染及代谢疾病等两个 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260901/c679479709.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260901/c679479709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664884462","title":"恒瑞医药HER2 ADC三期数据积极，国产ADC一线治疗竞争力提升｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2664884462","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664884462?lang=zh_cn&edition=full","pubTime":"2026-09-01 09:23","pubTimestamp":1788225791,"startTime":"0","endTime":"0","summary":"截至8月31日收盘，三大指数集体收涨，医药板块集体调整。医药ETF（512120）跟踪指数下跌1.46%，生物医药ETF（159508）跟踪指数下跌1.4%，港股通生物科技ETF（159102）跟踪指数下跌3.61%。相关个股中，泰格医药上涨5.9%，云南白药上涨0.78%，沃森生物下跌4.83%，长春高新下跌3.58%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609013860997079.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609013860997079.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0196","LU1781817850.SGD","LU2488822045.USD","01276","BK0239","LU0405327494.USD","LU1328615791.USD","LU2580892789.USD","LU2495084118.USD","LU2580892862.HKD","LU2097828714.EUR","LU0359201885.HKD","LU0359202008.SGD","LU1997245094.SGD","LU2543165471.USD","LU0405327148.USD","BK0028","159938","BK0188","LU1255011170.USD","600276","LU0359201612.USD","LU2097828631.EUR","LU2097828805.USD","LU1146622755.USD","BK0060","LU1820825898.SGD","LU1997245177.USD","LU2097828557.USD","LU2289578879.USD","BK1574","09939","BK1161","LU2148510915.USD","LU1064130708.USD","LU2097828474.EUR","BK1515","BK1191","LU1023057109.AUD","LU2328871848.SGD","BK0183","LU1064131003.USD","LU1969619763.USD","LU1655091616.SGD","LU1580142542.USD","BK0012","LU1997244956.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664881161","title":"迪哲医药(688192.SH)：与阿斯利康就舒沃哲®授权许可协议生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2664881161","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664881161?lang=zh_cn&edition=full","pubTime":"2026-09-01 08:44","pubTimestamp":1788223497,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)发布公告，公司于2026年7月14日与AstraZeneca UK Limited(以下简称“阿斯利康”)签署《许可协议》，授予阿斯利康在全球范围内独家开发、商业化舒沃哲®的权利。协议约定的协议生效条件已全部满足，协议于2026年8月31日正式生效。阿斯利康将于今年第四季度在美国实现舒沃哲®商业化。公司将获得阿斯利康支付的一次性、不可返还的首付款6亿美元，最高达4 亿美元的临床开发里程碑款项以及最高达5亿美元的销售里程碑款项，此外公司将获得按舒沃哲®全球销售额最高到低双位数的阶梯式比例的特许权使用费。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","688192","BK0239","BK1161","09939","BK1515","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664886538","title":"普莱医药二次递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2664886538","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664886538?lang=zh_cn&edition=full","pubTime":"2026-09-01 06:42","pubTimestamp":1788216120,"startTime":"0","endTime":"0","summary":"据港交所8月31日披露，普莱医药(江苏)股份有限公司(简称：普莱医药)向港交所主板递交上市申请，中信证券为其独家保荐人。该公司曾于2月13日向港交所提交上市申请。招股书显示，普莱医药是一 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260901/c679464076.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260901/c679464076.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664007784","title":"股市必读：森萱医药新发布《投资者关系活动记录表》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664007784","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664007784?lang=zh_cn&edition=full","pubTime":"2026-09-01 01:57","pubTimestamp":1788199032,"startTime":"0","endTime":"0","summary":"公司公告汇总：8月28日公司举办线上调研活动，披露上半年各业务板块收入与毛利率均增长，利润增速高于营收增速，明确未来五年布局宠物药新赛道战略。公司说明上半年经营情况，原料药、医药中间体、含氧杂环三大板块均实现收入增长，利润增速高于营收增速，毛利率持续提升；并介绍持续推进海外注册、降本增效及拓展海外市场以应对国内价格下行压力；同时阐述未来五年布局宠物药新赛道的战略原因。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100002206.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","159938","09939","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663005384","title":"力生制药：采立惠（www.cailihui.com）是力生制药子公司青春康源立和医药旗下品牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2663005384","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663005384?lang=zh_cn&edition=full","pubTime":"2026-08-31 20:51","pubTimestamp":1788180668,"startTime":"0","endTime":"0","summary":"三鱼数智目前尚处于初创起步阶段，后续若出现业务层面重大节点突破，公司将按规定及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100034352.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1574","002393","BK0188","09939","BK1161","BK1515","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663937072","title":"亚虹医药（688176）披露2026年半年度报告，8月31日股价下跌0.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663937072","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663937072?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:48","pubTimestamp":1788173298,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，亚虹医药报收于11.86元，较前一交易日下跌0.17%，最新总市值为67.86亿元。近日，江苏亚虹医药科技股份有限公司披露《2026年半年度报告》。本报告期实现营业收入155,353,308.79元，同比增长19.28%；利润总额为-244,770,829.97元；归属于上市公司股东的净利润为-238,604,759.91元；归属于上市公司股东的扣除非经常性损益的净利润为-250,930,825.16元。研发投入占营业收入的比例为127.67%，较上年同期增加38.23个百分点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100029627.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1161","09939","BK1515","BK0239","688176","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663071350","title":"迪哲医药（688192）披露舒沃哲新增适应症上市申请获美国FDA受理，8月31日股价下跌0.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663071350","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663071350?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:44","pubTimestamp":1788169497,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，迪哲医药报收于58.28元，较前一交易日下跌0.66%，最新总市值为271.1亿元。该股当日开盘57.87元，最高59.58元，最低57.5元，成交额达3.55亿元，换手率为1.32%。迪哲医药近日披露公告，公司自主研发的舒沃哲新增适应症上市申请已获美国FDA受理，拟用于一线治疗EGFR exon20ins的局部晚期或转移性非小细胞肺癌成人患者。该适应症在中国也已获NMPA受理并纳入优先审评，此前已获中美突破性疗法认定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100024818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK0239","BK1161","159938","BK1574","09939","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663902138","title":"A股午评：创业板指跌1.29%，影视院线板块爆发，黄金、医药板块跌幅居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2663902138","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663902138?lang=zh_cn&edition=full","pubTime":"2026-08-31 11:33","pubTimestamp":1788147214,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["KGLD","GDX","IAU","02840","159831","159982","OUNZ","AAAU","CEF","09939","DBC","GBUG","GDXD","IAUI","GDXU","XME","JDST","PICK","DUST","SGDM","399001","JNUG","GLDM","BEGS","GOLY","PHYS","03188","RING","399300","GDXJ","SGOL","GLL","UGL","BTGD","159938","USG","FAAR","FGDL","DZZ","GLTR","SHNY","PALL","BAR","DGP","399006","GDXY","UYM","IAUM","GOAU","DULL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663902673","title":"迪哲医药、剧星传媒递表港交所；星环科技通过港交所聆讯｜港交所早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2663902673","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663902673?lang=zh_cn&edition=full","pubTime":"2026-08-31 10:26","pubTimestamp":1788143206,"startTime":"0","endTime":"0","summary":"｜2026年8月31日星期一｜NO.1迪哲医药、剧星传媒递表港交所据港交所8月27日披露，迪哲（江苏）医药股份有限公司（以下简称迪哲医药，SH688192）、上海剧星传媒股份有限公司（以下简称剧星传媒）已向港交所主板递交上市申请。迪哲医药是一家处于商业化阶段的生物制药公司，公司的核心治疗领域是肿瘤及血液系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608313859847470.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608313859847470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91222","BK1515","159938","BK1128","BK1574","IPOS","BK1161","09939","01981"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663142026","title":"政策东风与产业升级交汇，双成药业站在医药价值重估的风口","url":"https://stock-news.laohu8.com/highlight/detail?id=2663142026","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663142026?lang=zh_cn&edition=full","pubTime":"2026-08-31 10:10","pubTimestamp":1788142214,"startTime":"0","endTime":"0","summary":"而那些具备扎实研发积淀与全球商业化视野的企业，正在这一轮洗牌中迎来真正的价值的窗口。报告期内，公司实现营业收入1.17亿元，同比增长39.27%；归属于上市公司股东的净利润1,362.78万元，同比增长173.80%；扣非净利润1,089.96万元，同比增长151.86%。分季度看，双成药业二季度营收环比增长41.86%，归母净利润环比增长195.21%。2026年上半年，该产品贡献收入6,153.56万元，占营业总收入的52.52%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026083100006622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002693","09939","BK1161","BK1515","159938","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663028039","title":"股市必读：白云山新发布《北京市中伦（广州）律师事务所关于广州白云山医药集团股份有限公司2026年第一次临时股东会的法律意见书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2663028039","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663028039?lang=zh_cn&edition=full","pubTime":"2026-08-31 08:22","pubTimestamp":1788135736,"startTime":"0","endTime":"0","summary":"广州白云山医药集团股份有限公司2026年第一次临时股东会决议公告广州白云山医药集团股份有限公司于2026年8月28日召开2026年第一次临时股东会，会议由董事长陈杰辉主持，采用现场与网络投票相结合方式召开，表决程序符合相关法律法规及公司章程规定。北京市中伦（广州）律师事务所对本次会议进行了见证并出具法律意见书，认为本次股东会决议合法有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100002316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0188","159938","00874","BK0097","BK1521","BK1606","BK1161","BK1191","BK0096","BK1574","BK0183","BK0196","BK0070","BK1197","600332","09939","BK0028","BK0012","BK0239","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663387028","title":"股市必读：亚虹医药中报 - 第二季度单季净利润同比下降60.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663387028","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663387028?lang=zh_cn&edition=full","pubTime":"2026-08-31 07:41","pubTimestamp":1788133269,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，亚虹医药报收于11.88元，下跌0.5%，换手率1.15%，成交量6.56万手，成交额7847.04万元。股本股东变化：截至2026年6月30日股东户数为2.4万户，较3月31日减少8.71%。业绩披露要点：2026年中报显示上半年主营收入1.55亿元，同比上升19.28%；归母净利润-2.39亿元，同比下降47.09%。第二季度单季度主营收入8426.74万元，同比上升21.89%；归母净利润-1.26亿元，同比下降60.4%；扣非净利润-1.35亿元，同比下降53.43%；负债率27.78%，投资收益995.97万元，财务费用445.18万元，毛利率74.25%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100001908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663709042","title":"股市必读：迪哲医药新发布《迪哲医药：关于重新向香港联交所递交H股发行上市申请并刊发申请资料的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2663709042","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663709042?lang=zh_cn&edition=full","pubTime":"2026-08-31 03:33","pubTimestamp":1788118390,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，迪哲医药报收于58.67元，上涨0.2%，换手率0.88%，成交量4.08万手，成交额2.39亿元。公司公告汇总：舒沃哲新增适应症上市申请获美国FDA受理，拟用于一线治疗EGFR exon20ins非小细胞肺癌。该适应症在中国也已获NMPA受理并纳入优先审评，此前已获中美突破性疗法认定。舒沃哲已在中美获批用于二/后线治疗，全球开发与商业化权利已授权给阿斯利康。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100001004.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK1574","BK1161","159938","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663475620","title":"议程一览｜科创出海，药启新程·2026上海国际医药健康创新与资本大会暨第15届医药CEO论坛（更新至0830）","url":"https://stock-news.laohu8.com/highlight/detail?id=2663475620","media":"国泰君安证券研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663475620?lang=zh_cn&edition=full","pubTime":"2026-08-30 22:09","pubTimestamp":1788098940,"startTime":"0","endTime":"0","summary":"重要提醒本订阅号所载内容仅面向国泰海通证券研究服务签约客户。因本资料暂时无法设置访问限制，根据《证券期货投资者适当性管理办法》的要求，若您并非国泰海通证券研究服务签约客户，为保证服务质量、控制投资风险，还请取消关注，请勿订阅、接收或使用本订阅号中的任何信息。法律声明本公众订阅号为国泰海通证券股份有限公司 研究所依法设立、独立运营的唯一官方订阅号。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MzEwMDEzNQ==&mid=2650541162&idx=1&sn=f817d9b55133fef5765c8311a3a65534&chksm=8987663dcece791c420d67f146d5294eb518972be80f823221005a8ccfa4d923f1e8a17bc767&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["159938","09939","BK1574","BK1161","BK1515","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663481270","title":"亚虹医药（688176）2026年中报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2663481270","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663481270?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:15","pubTimestamp":1788041741,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期亚虹医药发布2026年中报。根据财报显示，亚虹医药增收不增利。本次财报公布的各项数据指标表现一般。财报体检工具显示：建议关注公司现金流状况建议关注财务费用状况建议关注公司应收账款状况持有亚虹医药最多的基金为国联医疗健康混合A，目前规模为0.56亿元，最新净值1.2729，较上一交易日下跌1.3%，近一年上涨19.49%。本文数据来源于亚虹医药2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000002327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK0239","BK1574","688176","BK1515","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788254245055,"stockEarnings":[{"period":"1week","weight":0.0016},{"period":"1month","weight":-0.0031},{"period":"3month","weight":0.0917},{"period":"6month","weight":0.0321},{"period":"1year","weight":-0.1252},{"period":"ytd","weight":-0.0092}],"compareEarnings":[{"period":"1week","weight":0.0269},{"period":"1month","weight":0.0402},{"period":"3month","weight":-0.0218},{"period":"6month","weight":-0.0236},{"period":"1year","weight":0.0333},{"period":"ytd","weight":0.0044}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"医药(159938)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供医药(159938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"医药,159938,医药股票,医药股票老虎,医药股票老虎国际,医药行情,医药股票行情,医药股价,医药股市,医药股票价格,医药股票交易,医药股票购买,医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"医药(159938)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供医药(159938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}